At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Cediranib +1 moredrug
Likely dose
Cediranib 30 - 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Randomised, Phase 2 Study in Patients With Advanced Solid Tumours to Determine Effect of Food Upon Pharmacokinetics of a Single Oral Dose of Cediranib (AZD2171, Recentin™), Followed by an Assessment of the Safety & Tolerability of Fixed and Individualised Daily Dosing
In Brief
A Phase 2 clinical trial evaluating Cediranib and Cediranib 30 - 90 mg for Cancer. Completed, enrolled 60 participants across 4 sites.
Detailed Summary
The purpose of this study is to determine whether food has any effect on a single dose of Cediranib (AZD2171, Recentin™)followed by an assessment of the safety and tolerability of fixed daily dosing in comparison to varying dose levels on a patient-by-patient basis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2006
Enrollment StartJun 2006
Primary CompletionJan 2008
Study CompletionSep 2008
TodayJul 2026
First PostedMar 27, 2006
Enrollment StartJun 1, 2006
Primary CompletionJan 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 20.3 years ago
Interventions
Cediranibdrug
45 mg oral dose
Cediranib 30 - 90 mgdrug
oral tablet dose escalation